Benefit-Risk Evidence for HTA Bodies: Extending Regulatory Analysis

The Regulatory-Reimbursement Gap

A decade ago, pharmaceutical companies could reasonably expect that regulatory approval from the FDA or EMA would lead directly to market access across developed economies. Today, that assumption no longer holds. In the United Kingdom, NICE rejects approximately 20% of regulatory-approved medicines as not cost-effective. In Germany, G-BA assigns "no added benefit" to nearly 40% of new drugs undergoing early benefit assessment. Even in the United States, where formal HTA is less centralized, pharmacy benefit managers and payer organizations increasingly require comparative effectiveness evidence before granting formulary access.

This divergence stems from fundamentally different questions. Regulatory agencies ask: "Is this medicine safe and effective for its intended use?" HTA bodies ask: "Does this medicine offer meaningful improvement over existing treatments, and is that improvement worth the additional cost?" The first question can often be answered with placebo-controlled trials. The second requires active-comparator evidence, patient-reported outcomes, real-world effectiveness data, and health economic modeling.

The Evidence Timing Problem

Most pharmaceutical companies design their clinical development programs to satisfy regulatory requirements first, with HTA considerations treated as a post-approval concern. This sequential approach creates significant delays. By the time regulatory approval is secured, the HTA evidence package is incomplete: comparative effectiveness analyses haven't been conducted, health utility data hasn't been collected, and real-world evidence hasn't accumulated. Companies then face 12-18 month delays while scrambling to generate payer-grade evidence, hemorrhaging revenue during the critical launch window.

ArcaScience's approach enables parallel evidence generation: designing the regulatory BRA framework from the start to also support comparative effectiveness analysis, PRO integration, and health economic input extraction. This parallelization compresses time-to-reimbursement by 40-60%, transforming market access from a post-approval afterthought into a strategic advantage embedded in clinical development.

The AS Profiling Base as Universal Evidence Layer

The challenge of serving both regulatory and HTA audiences from a single evidence base has historically seemed insurmountable. Regulatory submissions emphasize absolute safety and efficacy. HTA submissions emphasize relative effectiveness and value. The data structures, analytical methodologies, and presentation formats differ so dramatically that most companies maintain entirely separate evidence streams.

ArcaScience's solution centers on the AS Profiling Base: a unified data architecture that captures clinical trial results, real-world evidence, safety surveillance, literature evidence, and patient-reported outcomes in a standardized, queryable format. This architecture enables both regulatory BRA and comparative effectiveness analysis because it structures evidence around therapeutic decisions rather than submission templates.

For regulatory BRA, the platform generates value trees that map therapeutic goals to safety/efficacy endpoints, produces effects tables with absolute risk measures, and performs scenario modeling for benefit-risk trade-off visualization. For HTA submissions, the same underlying evidence base powers relative benefit-risk analysis against standard of care, network meta-analyses for indirect treatment comparison, health utility mapping from clinical endpoints to quality-of-life scores, and economic model input extraction for cost-effectiveness analysis.

Jurisdiction-Specific Adaptation Engines

Beyond evidence reuse, ArcaScience automates the translation of evidence into jurisdiction-specific HTA formats. NICE requires a particular company submission template structure with specific cost-effectiveness modeling conventions. G-BA demands endpoint hierarchies aligned with patient-relevant outcomes and strict comparator definitions. HAS uses an entirely different value framework based on ASMR ratings and clinical added value levels.

The platform's adaptation engines apply these jurisdiction-specific rules automatically: selecting appropriate comparators based on local treatment guidelines, mapping endpoints to payer-recognized patient benefit categories, formatting evidence tables to match submission templates, and flagging evidence gaps that require supplementary analysis. This automation reduces the manual burden of multi-country HTA submissions from months to weeks, while ensuring that each dossier speaks the specific evidentiary language that local HTA bodies expect.